SANTA ANA, Calif. — September 18, 2025 — Leads & Copy — Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen Biotech, will present at the 3rd China Great Bay Cell and Gene Therapy Forum in Guangzhou, China, from September 25-26, 2025.
Dr. Song will discuss the scientific rationale and recent clinical data supporting troculeucel, an investigational autologous enhanced NK cell therapy, for neurodegenerative diseases. NKGen is focused on advancing innovative NK cell-based approaches in the cell and gene therapy field.
The forum, hosted in Guangzhou Knowledge City, will host over 1200 experts and feature more than 90 speakers. It fosters innovation and collaboration across cell and gene therapy, RNA therapeutics, and stem cell research, uniting voices from biotech startups to global pharmaceutical leaders.
NKGen’s presentation, titled “Use of Troculeucel (Autologous Enhanced Natural Killer Cell Therapy) for Neurodegenerative Diseases – Scientific Rationale and Latest Clinical Data,” will be part of the Next Generation Cell Therapy track on September 25, 2025, from 3:20 PM – 3:45 PM China Standard Time (CST) at the Sino-Singapore Guangzhou Knowledge City International Convention and Exhibition Center.
A copy of the presentation will be available on NKGen’s website under the Scientific Publications section after the event. Previously disclosed data on troculeucel for neurodegenerative disease can also be found on the same page. For updates on clinical trials and regulatory announcements, visit the Company’s News page.
Troculeucel, also known as SNK01, is a cell-based, patient-specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate being developed by NKGen for neurodegenerative disorders and a range of cancers. The World Health Organization (WHO) has assigned troculeucel as the International Nonproprietary Name (INN) for SNK01.
Denise Chua, MBA, CLS, MLS (ASCP)
SVP, Corporate Affairs
949-396-6830
dchua@nkgenbiotech.com
Source: NKGen Biotech
